IBRX
Cue the lawyers
ImmunityBio is back in the headlines, and not for the shiny kind of biotech news. The company is facing a securities class action lawsuit after the FDA sent a warning letter over allegedly misleading efficacy claims tied to Anktiva, its lead biologic.
Why investors should care
The lawsuit covers investors who bought ImmunityBio stock between January 19 and March 24, 2026 — basically the kind of window that makes plaintiffs’ firms very, very busy. The stock already got punished, falling more than 21% on March 24 when the FDA issue came out, so this is less of a fresh plot twist and more of the sequel nobody asked for.
The bigger headache
This isn’t just about one warning letter. It raises the kind of credibility questions that can hang over biotech names like a rain cloud:
- regulatory scrutiny from the FDA
- potential legal costs and distractions
- the risk that sales and adoption of Anktiva get banged up if confidence slips
Big picture
ImmunityBio’s still a cancer-focused biotech with an approved product in Anktiva, but when regulators start side-eyeing the messaging and shareholders start filing suit, the road gets a lot bumpier. In biotech, perception can move almost as fast as the science — and sometimes faster.